Featured Content by Stephanie Vogel
Video
Webcast: Advanced IBD Medications: Understanding Mechanisms of Action
Understanding the mechanisms of action of advanced inflammatory bowel disease (IBD) medications is essential for optimizing treatment strategies for patients with Crohn’s disease and ulcerative colitis. In this educational webinar, Brooke Hodnik, Physician Assistant at Texas Digestive Disease Consultants, explores the evolving landscape of IBD biologics and small molecule therapies, including TNF inhibitors, integrin inhibitors, IL-12/23 and IL-23 inhibitors, JAK inhibitors, and S1P receptor modulators. Learn how these advanced IBD treatments target different inflammatory pathways, their clinical benefits and potential risks, and how to select appropriate therapies based on disease severity, extraintestinal manifestations (EIMs), comorbidities, and individual patient needs. Brooke discusses commonly used Crohn’s disease and ulcerative colitis medications, including infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, guselkumab, mirikizumab, upadacitinib, tofacitinib, ozanimod, and etrasimod. The presentation also highlights important considerations for medication safety, therapeutic drug monitoring, treatment response, infection screening, vaccination, and managing potential side effects. Discover practical approaches to understanding primary nonresponse and loss of response to biologic therapy, evaluating treatment options for patients with overlapping inflammatory conditions, and balancing medication risks with the consequences of uncontrolled IBD. This session provides valuable insights for gastroenterology healthcare professionals and advanced practice providers (APPs) seeking to personalize IBD treatment decisions, improve patient education, and achieve long-term, steroid-free disease control.
Learn More